North America Medication-Assisted Treatment (MAT) Market – Industry Trends and Forecast to 2029

Market Analysis and Insights

The Food and Drug Administration (FDA) approved three clinical drugs: buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime.

Market Definition

Medication-assisted treatment (MAT) involves using medications, combined with counselling and behavioural therapies, to provide a complete patient approach for treating substance use disorders. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and Substance Abuse and Mental Health Services Administration (SAMHSA) naloxone is one of many medications considered essential to a functioning health care system. The North America medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted (MAT) treatment market will grow at a CAGR of 9.7% from 2022 to 2029.

North America Medication-Assisted Treatment (MAT) Market Dynamics

Drivers

•  The Rise In Incidence Of Alcohol Use Disorder And Opioid Use Disorders

Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, and alcohol addiction. Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.

For instance,

• In 2022, the data by World Health Organization (WHO) European Region stated that alcohol disorder causes 1 million deaths annually

As the companies are constantly engaged in research and developmental activities, the knowledge about the incidence of alcohol use disorder and opioid use disorders would help in finding novel solutions and that would aid in more collaborations and partnerships with market players in countries such as the U.S., Europe, and Asia-Pacific region. This signifies the increase in research and development-related investments for the initiation of generic medications in medication-assisted treatment (MAT) which is expected to boost the market growth.

• The Funding By The Government For Medication-Assisted Treatment (MAT)

Despite the established effectiveness of pharmacotherapies for treating opioid use and alcohol disorders, limitations to implementing medications for addiction treatment (MAT) by specialty treatment programs have been observed. Particular attention needs to be paid to specific sources for funding, organizational structure, and workforce resources, making a long-term investment that aligns the payment with the potential future beneficiaries.

For instance,

• In January 2021, according to the Federal Register of Government, The Rural Community Development Initiative Grants (RCDI) provided funding to intermediary organizations that deliver financial and technical assistance to recipients to help meet the needs of their communities in eligible rural areas

            The funding by the government would result in the patient's safety and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence the advancements in research and development activities and funding by the government are expected to drive the market growth.

Opportunity

• Rise In Healthcare Expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.

For instance,

•  In February 2021, according to Health Care Price Index (HCPI), the total U.S. healthcare budget had increased by 3.4%. The increase in growth states the federal government spending decreased significantly in the previous year from USD 287,000 million in 2020 to USD 170,000 million in 2021

Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favourable factor. The above are expected to create lucrative opportunities for the medication-assisted treatment (MAT) market.

Restraint/Challenge

• Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) involves using medications collated with counselling and behavioral therapies to provide a "whole-patient" approach as part of the comprehensive treatment strategy. Therefore, the present high cost is expected to show a descending trend. MAT is most effective for treating alcohol and opioid use disorders. However, specific side effects have been reported.

For instance,

• Methadone and buprenorphine, the generic medications, are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects

The adverse complications reported would lead to a decline in sales of the medicated opioid dependency medications, which would limit the sales of the medicines. In addition, it would affect the reliability of manufacturers involved in this market and hence be expected to restrain the market growth.

The medication-assisted treatment (MAT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Medication-assisted (MAT) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on the Medication-Assisted (MAT) Treatment Market

During the pandemic, medication-assisted treatment remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during Covid-19 Medication for opioid use disorder (MOUD) services are key to addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.

Recent Development

• In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations

North America Medication-Assisted Treatment (MAT) Market Scope

The medication-assisted (MAT) treatment market is segmented on the basis of eight segments: type, products, drug type, and dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Medication
• Therapy

On the basis of type the North America medication-assisted treatment (MAT) market is segmented into medication and therapy.

Products

• Buprenorphine and Naloxone
• Naltrexone
• Buprenorphine
• Methadone
• Naloxone
• Disulfiram
• Acamprosate

On the basis of products, the North America medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.

Drug Type

• Generics
• Branded

On the basis of drug type, the North America medication-assisted treatment (MAT) market is segmented into generics and branded.

Dosage Form

• Immediate Release
• Extended Release

On the basis of dosage form, the North America medication-assisted treatment (MAT) market is segmented into immediate release and extended release.

Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the North America medication-assisted treatment (MAT) market is segmented into oral, parenteral and others.

Population Type

• Adults
• Teenage

On the basis of population type, the North America medication-assisted treatment (MAT) market is segmented into adults and teenage.

End User

• Rehabilitation Clinics
• Hospitals
• Specialty Centers
• Homecare
• Others

On the basis of end user, the North America medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, speciality centers, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Direct Tender
• Retail Pharmacy
• Online Pharmacy
•  Others

On the basis of distribution channel, the North America medication-assisted treatment (MAT) market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others.

Medication-Assisted (MAT) Treatment Market Regional Analysis/Insights

The North America medication-assisted treatment (MAT) market is analysed and market size insights and trends are provided by regions, product type, type, application, workflow, end user and distribution channel as referenced above.

The countries covered in the medication-assisted (MAT) treatment market report are U.S., Canada and Mexico.

The U.S. is expected to dominate the market due to a rise in opioid dependency on medication, healthcare expenditure, and pharmaceutical companies.

The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Medication-Assisted (MAT) Treatment Market Share Analysis

The North America medication-assisted treatment (MAT) market competitive landscape provides details of a competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus on the medication-assisted (MAT) treatment market.

Some major players operating in the medication-assisted (MAT) treatment market are Indivior PLC, Orexo US Inc (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, VistaPharm, Inc., Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc.

SKU-68670